Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JTK-656
- Development stage
- Unknown
- Lead developer
- Japan Tobacco
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JTK-656 is a small molecule Toll-like receptor 7 (TLR7) agonist developed by Japan Tobacco Inc. for the potential treatment of infections in patients with immune deficiencies. By selectively activating TLR7, which is predominantly expressed in endosomes of plasmacytoid dendritic cells and B cells, JTK-656 triggers signaling pathways that lead to the secretion of Type I interferons (such as IFN-alpha) and other pro-inflammatory cytokines. This mechanism is intended to bolster the innate immune response and enhance the clearance of pathogens. Clinical evaluation has progressed through Phase 1 trials, including single ascending dose studies in healthy volunteers to assess safety, tolerability, and the impact of food on its pharmacokinetic profile.
Beyond the preview
Go deeper on JTK-656.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JTK-656.